Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Payables: 2023-2025

Historic Payables for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $848,000.

  • Artiva Biotherapeutics' Payables fell 30.21% to $848,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2024, which is 82.57% up from last year.
  • Artiva Biotherapeutics' Payables amounted to $848,000 in Q3 2025, which was down 30.21% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Payables peaked at $2.0 million during Q1 2025, and registered a low of $614,000 during Q4 2023.
  • Moreover, its 3-year median value for Payables was $1.1 million (2024), whereas its average is $1.1 million.
  • In the last 5 years, Artiva Biotherapeutics' Payables surged by 82.57% in 2024 and then crashed by 30.21% in 2025.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Payables stood at $614,000 in 2023, then spiked by 82.57% to $1.1 million in 2024, then plummeted by 30.21% to $848,000 in 2025.
  • Its Payables stands at $848,000 for Q3 2025, versus $1.2 million for Q2 2025 and $2.0 million for Q1 2025.